Transfer-promoting derivative removal system and application thereof
The risk of tumor metastasis and recurrence is solved by clearing circulating tumor cells and tumor exosomes using specific immunosorbents in the blood, and a representative tumor sample is provided for diagnosis and treatment, improving treatment effect and accurate detection sex.
Patent Information
- Application Number
- CN202310521332.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology cannot effectively prevent circulating tumor cells and tumor exosomes from being distributed to distal organs through the blood circulation, resulting in a high risk of tumor metastasis and recurrence. At the same time, the existing detection technology has sampling deviations during in vitro analysis, resulting in false negative results. .
Provide a pro-metastasis derivative removal system, including a capture column, an intravenous catheter, an indwelling needle and a peristaltic pump, to specifically adsorb circulating tumor cells and tumor exosomes using chimeric immunosorbents that bind ligands to purify blood and collected for diagnosis and treatment.
Effectively inhibit the distribution of pro-metastasis derivatives to distal organs, reduce the probability of tumor metastasis, improve the cure rate, and collect representative tumor samples through immunosorbents to guide diagnosis and treatment.
Smart Images

Figure CN118924982A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology and relates to a metastasis-promoting derivative clearance system and application thereof. Background Art
[0002] About 90% of cancer-related deaths are caused by cancer metastasis, and the treatment is ineffective. Hematogenous metastasis is the main mode of metastasis. Circulating tumor cells fall off from the primary tumor and enter the peripheral blood circulation, evade the recognition of the immune system, and infiltrate distant organs to form metastases. The number of circulating tumor cells in the peripheral blood of tumor patients is closely related to the metastasis and recurrence of cancer. It is worth noting that there is increasing evidence that tumor exosomes (a small extracellular vesicle secreted by tumor cells, with a size of 30-150nm) are also the culprits for initiating tumor metastasis. Tumor exosomes act as messengers, which are sent into the blood circulation by the primary tumor and reach specific distal organs, preparing pre-metastatic niches for their colonization even before the arrival of circulating tumor cells. The "seed soil" hypothesis describes the colonization of circulating tumor cells (seeds) in the pre-metastatic niche (soil) to promote tumor metastasis. Tumor exosomes are like fertilizers, making the soil (pre-metastatic niche) fertile and conducive to the growth of seeds (circulating tumor cells). Early studies have shown that circulating tumor cells and tumor exosomes are organotropic and can reach specific distal organs through the blood circulation and form metastases. Unfortunately, cancer patients who have received traditional anti-tumor treatments, such as surgical resection, radiotherapy, chemotherapy, etc., still have a great risk of tumor metastasis and recurrence due to the increase of circulating tumor cells and tumor exosomes in the blood.
[0003] So far, there is no mature technology that can simultaneously prevent circulating tumor cells and tumor exosomes from being distributed to distant organs through the blood circulation. In addition, there are many other metastasis-promoting derivatives in the blood, such as metastasis-promoting cytokines, circulating tumor DNA, and metastasis-promoting tumor-associated cells. Therefore, it is urgent to propose a system that can efficiently remove metastasis-promoting derivatives to prevent circulating tumor cells and tumor exosomes and other metastasis-promoting derivatives from reaching distant organs and inhibit tumor metastasis and recurrence.
[0004] In addition, circulating tumor cells, tumor exosomes and primary tumor tissues have great similarities in genomic mutations, gene expression, protein expression, etc., and can be used as liquid biopsy markers for non-invasive diagnosis. However, the current detection technology only accounts for one thousandth of the total blood volume (5-10mL) used for in vitro analysis, and there is sampling bias, leading to false negative results. Therefore, it is necessary to develop a system that can process systemic peripheral blood on a large scale and efficiently enrich metastatic derivatives to collect representative tumor samples for downstream analysis. Summary of the invention
[0005] Purpose of the invention: The purpose of the present invention is to provide a system for removing metastatic derivatives, which can draw the patient's blood out of the extracorporeal circulation device, remove the metastatic derivatives in the blood, such as circulating tumor cells, tumor exosomes, etc., and then transport the purified blood back to the human blood circulation, significantly inhibiting the distribution of metastatic derivatives to distal organs, effectively reducing the probability of distal tumor metastasis, reducing harm to patients, and improving the cure rate of patients. At the same time, it can release and collect tumor samples, such as circulating tumor cells and tumor exosomes, from the immunosorbent, which has guiding significance for the diagnosis and treatment of patients.
[0006] Technical solution: The purpose of the present invention is achieved through the following technical solution:
[0007] The present invention provides a metastasis-promoting derivative removal system, comprising one or more capture columns, a venous catheter, an indwelling needle and a peristaltic pump; the removal system is connected in the order of the indwelling needle, the venous catheter, the capture column, the peristaltic pump, the venous catheter and the indwelling needle;
[0008] The capture column is filled with an immunosorbent that removes metastasis-promoting derivatives;
[0009] The metastasis-promoting derivative clearing system allows the metastasis-promoting derivatives in the blood flowing through the capture column to be specifically adsorbed on the surface or inside of the immunosorbent, and then the purified blood is returned to the body.
[0010] The surface or interior of the immunoadsorbent is embedded with a ligand that specifically binds to the metastasis-promoting derivative.
[0011] The ligand is one or more of tumor-specific antibodies, polypeptides, nucleic acid aptamers or small molecules; preferably two or more of anti-epithelial cell adhesion protein (EpCAM), cytokeratin (cytokeratin, CK), vascular endothelial growth factor (vascular endothelial growth factor, VEGF), epidermal growth factor receptor 1 (epidermal growth factor receptor, EGFR), and proto-oncogene human epidermal growth factor receptor 2 (human epidermal growth factor receptor-2, HER2) antibodies.
[0012] The small molecule is hyaluronic acid or lectin.
[0013] The carrier material of the immunosorbent is one or more of agarose, polystyrene-divinylbenzene resin, polyethylene, polyvinyl alcohol, polypropylene, polyacrylamide, polyacrylic acid, polyacrylate, cellulose, chitin or carbon nanotubes, preferably agarose.
[0014] The immunosorbent is prepared according to the following method: using agarose gel microspheres as carriers, using epichlorohydrin to epoxidize the agarose gel microspheres, and in a carbonate buffer, using the amino or thiol groups of ligand molecules such as antibodies to undergo a ring-opening reaction with epoxy groups to achieve ligand coupling to obtain the immunosorbent.
[0015] The immunosorbent is a spherical structure with an average particle size of 10-1000 μm and a porous structure with a pore size distribution range of 10 nm-200 nm.
[0016] The working principle of the immunoadsorbent is: allowing large-sized metastasis-promoting derivatives to be specifically adsorbed on the surface, such as circulating tumor cells; small-sized metastasis-promoting derivatives can be specifically adsorbed on the surface, and can also be adsorbed inside through the dual effects of molecular sieving and specific adsorption, such as tumor exosomes and metastasis-promoting cytokines.
[0017] The metastasis-promoting derivatives include circulating tumor cells, tumor exosomes, metastasis-promoting cytokines (including but not limited to vascular endothelial growth factor, transforming growth factor-β, interleukin 4, interleukin 10), circulating tumor DNA, and metastasis-promoting tumor-associated cells (including but not limited to tumor-associated fibroblasts and tumor-associated macrophages).
[0018] The metastasis-promoting derivatives mainly refer to circulating tumor cells and tumor exosomes.
[0019] The metastatic derivative clearance system of the present invention uses 0.25% trypsin-EDTAU to elute the specifically bound circulating tumor cells; uses pH 2.2 glycine-hydrochloric acid buffer to elute the specifically bound tumor exosomes, and collects them for downstream analysis.
[0020] The present invention also provides an application of the metastasis-promoting derivative removal system: a metastasis-promoting derivative perfusion system. The metastasis-promoting derivative perfusion system of the present invention comprises an arterial pressure gauge, a blood pump, a heparin pump, an inflow pressure gauge, a degassing system, a venous pressure gauge, and the metastasis-promoting derivative removal system; the arterial pressure gauge, the blood pump, the heparin pump, the inflow pressure gauge, the metastasis-promoting derivative removal system, the degassing system, and the venous pressure gauge are sequentially connected through an extracorporeal blood pipeline;
[0021] The blood pump provides power for extracorporeal blood circulation; the heparin pump provides heparin to the blood to prevent coagulation; the pro-metastasis derivative removal system is used to remove pro-metastasis derivatives, such as circulating tumor cells, tumor exosomes, etc.; the purified blood is transported to the patient after the bubbles are removed by the degassing system and the blood is tested to be qualified by the venous pressure gauge.
[0022] Beneficial effects:
[0023] The pro-metastasis derivative clearance system provided by the present invention fills the capture column with an immunosorbent, and the patient's blood flows through the capture column, and the pro-metastasis derivatives in the blood are specifically adsorbed to the surface or inside of the adsorbent; it not only effectively removes the pro-metastasis derivatives in the blood, including circulating tumor cells, tumor exosomes, etc., but also inhibits their distribution to distal organs and reduces the probability of tumor metastasis; at the same time, it can release and collect tumor samples from the immunosorbent, such as circulating tumor cells and tumor exosomes, which has guiding significance for the diagnosis and treatment of patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Schematic diagram of the clearance of circulating tumor cells and tumor exosomes by the pro-metastatic derivative clearance system;
[0025] Among them, 1-arterial pressure gauge, 2-blood pump, 3-heparin pump, 4-inflow pressure gauge, 5-pro-metastatic derivative removal system, 6-degassing system, 7-venous pressure gauge;
[0026] Figure 2 Schematic diagram of the preparation of immunosorbent;
[0027] Figure 3 The results are for the characterization of the immunosorbent; Figure 3 A is the fluorescence image of the immunosorbent; Figure 3 B is the antibody coupling density;
[0028] Figure 4 characterization results for the capture of circulating tumor cells and tumor exosomes by immunoadsorbents; Figure 4 A is a fluorescent image of the specific adsorption of tumor cells by the immunoadsorbent; Figure 4 B is a fluorescence image of the specific adsorption of tumor exosomes by the immunoadsorbent; Figure 4 C is the fluorescence spectrum of the immunoadsorbent before and after specific adsorption of tumor cells; Figure 4 D is the fluorescence spectrum of the immunoadsorbent before and after specific adsorption of tumor exosomes;
[0029] Figure 5 is the result of the removal efficiency; Figure 5 A is the standard curve of stained tumor cell suspension (fluorescence intensity-cell concentration); Figure 5 B is the standard curve of the stained tumor exosome suspension (fluorescence intensity-cell concentration); Figure 5 C is the effect of the immunosorbent filling amount on the clearance efficiency during capture; Figure 5 D is the effect of cycle time on removal efficiency;
[0030] Figure 6 To characterize the tumor cells and tumor exosomes released from the immunoadsorbent; Figure 6 A is the release efficiency of circulating tumor cells and tumor cells; Figure 6 B is a transmission electron microscopy image of tumor exosomes after elution; Figure 6 C is the particle size distribution of tumor exosomes after elution; Figure 6 D is the Calcein-AM and PI co-staining image of tumor cells after release; Figure 6 E is the proliferation ability of tumor cells after release. DETAILED DESCRIPTION
[0031] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.
[0032] The clearance efficiency of circulating tumor cells (CTCs) and tumor exosomes (TDEs) was calculated as follows:
[0033] MDA-MB-468 cells were stained with DAPI for 10 min in the dark, and a series of cell density gradients were set. The fluorescence spectra of MDA-MB-468 cells with different density gradients were recorded using a multifunctional enzyme analyzer, with the emission slit set to 5 nm and the excitation wavelength set to 360 nm. The fluorescence emission wavelength was set in the range of 400-560 nm. At the same time, the fluorescence intensity at the excitation wavelength of 360 nm and the emission wavelength of 460 nm was recorded for fitting the standard curve. Exosomes were stained with DiR, and the excess DiR was washed away with an AmiconUltra 100-kDa ultrafiltration tube. The fluorescence spectra of exosomes were recorded using a multifunctional enzyme analyzer, with the emission slit set to 10 nm and the excitation set to 708 nm. The fluorescence emission wavelength was set in the range of 748-780 nm. In addition, the fluorescence intensity at the excitation wavelength of 708 nm and the emission wavelength of 768 nm was recorded for fitting the standard curve and was used as a quantification tool for clearance. The capture efficiency of model CTCs and TDEs was calculated according to the following formula:
[0034]
[0035]
[0036] Among them, C E is the capture efficiency of CTCs or TDEs, N1 is the initial number of model CTCs added, and N2 is the number of free model CTCs in the supernatant after capture (calculated based on the fluorescence intensity, volume and standard curve of the sample).
[0037] M1 is the initial amount of model TDEs added (μg), and M2 is the amount of free TDEs in the supernatant after capture (calculated based on the fluorescence intensity of the sample, volume, and standard curve).
[0038] Taking MDA-MB-468 breast cancer cells as model circulating tumor cells and its exosomes as model tumor exosomes as examples, the metastasis-promoting derivative clearance system of the present invention is used to clear circulating tumor cells and tumor exosomes from peripheral blood, and they are collected from the immunoadsorbent for use as tumor samples.
[0039] Example 1 Preparation and Characterization of Immunosorbent
[0040] Agarose gel microspheres (purchased from Beijing Ruida Henghui Technology Development Co., Ltd.; model: Sepharose 6FF; average particle size: 124 μm) were used as carriers. Figure 2 The immunosorbent was prepared by the indicated route.
[0041] The specific preparation steps are:
[0042] (1) 300 mg of washed and drained Sepharose 6FF agarose gel microspheres were suspended in 3.5 mL of dimethyl sulfoxide (DMSO), mixed with 1 mL of 0.4 M sodium hydroxide solution, and 0.5 mL of epichlorohydrin was added. The suspension was shaken at room temperature for 5 hours at a speed of 100 rpm. It was transferred to a G4 sand core funnel and the gel was washed with 100 mL of ultrapure water to obtain epoxidized agarose gel.
[0043] (2) Prepare antibody solution in carbonate buffer (0.1 M, pH = 11): prepare 20 μg mL -1 The anti-EpCAM and anti-EGFR antibody mixed solution, a total of 500 μL, was purchased from Santa Cruz Biotechnology (Shanghai) Co., Ltd.
[0044] (3) The mixed antibody solution was added to a 2 mL Eppendorf (EP) tube containing 50 mg of epoxidized agarose gel, and placed in a constant temperature shaker at 37°C and 100 rpm overnight to obtain an immunosorbent functionalized with anti-EpCAM and anti-EGFR antibodies. The immunosorbent was spherical, with an average particle size of 124 μm and an average pore size of 40 nm.
[0045] Characterization of Immunosorbents:
[0046] In order to visualize the antibody coupling results, we used fluorescent antibodies, namely FITC-labeled anti-EGFR antibody, Alexa Fluor 647 labeled anti-EpCAM antibody. Figure 3 As shown in A, through laser confocal imaging, two antibodies can be successfully coupled to agarose gel microspheres at the same time. Figure 3As shown in B, the results show that the higher the concentration of anti-EpCAM antibody, the higher the antibody coupling density. -1 Theoretically, each milligram of immunosorbent has 2.54×10 11 The combined binding sites can be used to capture circulating tumor cells and tumor exosomes. All these results indicate that the conjugated antibody density is high enough to mediate immune recognition between circulating tumor cells, tumor exosomes, and tumor-specific antibodies grafted on the immunoadsorbent.
[0047] Example 2 Recognition and capture of circulating tumor cells and tumor exosomes by immunoadsorbents
[0048] (1) Capture ability of anti-EpCAM antibody-functionalized agarose gel microspheres on MDA-MB-468 cells
[0049] Preparation of anti-EpCAM antibody functionalized agarose gel microspheres: First, prepare 20 μg mL -1 The anti-EpCAM antibody solution was prepared according to the method of Example 1 to obtain single antibody functionalized agarose gel microspheres.
[0050] First, 50 mg of anti-EpCAM antibody-functionalized agarose gel microspheres were placed in a 2 mL EP tube, and then 2 × 10 5 MDA-MB-468 cells (from ATCC) were added and PBS was added to 500 μL, and then placed in a constant temperature shaker at 37° C. and 100 rpm for 1 hour.
[0051] To visualize the immunoadsorbents capturing CTCs, FITC-labeled anti-EpCAM antibody was used as the capture antibody, while tumor cells were labeled with DiD. After capture, the immunoadsorbents were washed three times with PBS to remove nonspecific molecules adsorbed on the surface of the microspheres, and stereoscopic imaging was performed using a confocal laser scanning microscope (overlay Z-stock mode, taking a picture every 5 μm) and photographed.
[0052] (2) Characterization of tumor exosome capture by immunoadsorbents
[0053] We performed immunofluorescence analysis using CD81 antibody to specifically label tumor exosomes.
[0054] 50 mg of anti-EpCAM antibody-functionalized agarose gel microspheres were placed in a 2 mL EP tube, and then 50 μg (total exosome protein) of MDA-MB-468 cell-derived exosomes (exosomes were isolated and prepared by ultracentrifugation) were added and supplemented with PBS to 500 μL, and then shaken at a constant temperature of 37°C and 100 rpm for 1 hour.
[0055] In order to visualize the immunoadsorbents that captured tumor exosomes, immunofluorescence staining analysis was used for characterization. After centrifugation (1000 rpm, 3 min), the supernatant was discarded and the immunoadsorbent was thoroughly washed three times with PBS to remove nonspecific molecules adsorbed on the surface of the microspheres. The samples were blocked with 5% BSA / PBS for 1 hour at room temperature and then incubated with CD81 rabbit polyclonal antibody (purchased from Biyuntian Biotechnology, diluted 1:200 with PBS) at 4°C overnight. Subsequently, Alexa Fluor The samples were stained with 647-labeled goat anti-rabbit IgG (purchased from Bio-Tech Biosciences, diluted 1:500 in PBS) at room temperature for 1 hour. Finally, confocal laser scanning microscopy was used for imaging and photography.
[0056] (3) Comparison of fluorescence intensity of suspension before and after capture
[0057] MDA-MB-468 cells were stained with DAPI for 10 minutes; its exosomes were stained with DiR for 30 minutes. The above capture process was repeated, and the fluorescence spectra of tumor cells and tumor exosome suspensions before and after capture were detected using a multifunctional microplate reader.
[0058] Experimental results:
[0059] Through confocal imaging (overlay z-stock), we can see that Figure 4 As shown in A, the immunosorbent can clearly capture MDA-MB-468 cells. At the same time, we repeated the above capture steps using DAPI-stained MDA-MB-468 cells, as shown in Figure 4 As shown in C, it was found that the fluorescence intensity of the stained cell suspension decreased significantly before and after capture, further proving that the circulating tumor cells were successfully captured, resulting in a decrease in the number of free cells in the supernatant and thus a decrease in fluorescence intensity.
[0060] like Figure 4 As shown in Figure B, when a fluorescent antibody against CD81 was used, a strong fluorescent signal was observed on the surface of the immunosorbent, indicating that exosomes with complete vesicle structure could be specifically captured by the anti-EpCAM antibody on the surface of the immunosorbent. Subsequently, we also found that the fluorescence intensity of the stained exosome suspension changed significantly before and after capture, as shown in Figure 2. Figure 4D. This indicates that tumor exosomes were captured by the immunoadsorbent, and the free tumor exosomes in the supernatant decreased, resulting in a decrease in fluorescence intensity.
[0061] Therefore, the experimental results further demonstrated that tumor exosomes were successfully captured.
[0062] Example 3 Clearance efficiency of the metastasis-promoting derivative clearance system on circulating tumor cells and tumor exosomes
[0063] (1) Establishment of standard curves for tumor cell and tumor exosome suspensions
[0064] MDA-MB-468 cells were stained with DAPI for 10 min in dark conditions, and a series of cell density gradients were set up. The fluorescence intensity of MDA-MB-468 cells with different density gradients was recorded with an excitation wavelength of 360 nm and an emission wavelength of 460 nm using a multifunctional enzyme analyzer for fitting the standard curve. Exosomes were stained with DiR, and excess DiR was washed away with an Amicon Ultra 100-kDa ultrafiltration tube. The fluorescence intensity with an excitation wavelength of 708 nm and an emission wavelength of 768 nm was recorded using a multifunctional enzyme analyzer for fitting the standard curve.
[0065] By setting a series of concentrations of stained cell suspensions and exosome suspensions, it was found that the fluorescence intensity had a good linear relationship with the corresponding circulating tumor cells or tumor exosome concentrations, such as Figure 5 A. Figure 5 B. Therefore, it is used as a quantitative tool for capture efficiency. The removal efficiency is calculated according to the following formula.
[0066]
[0067]
[0068] Among them, C E is the capture efficiency of CTCs or TDEs, N1 is the initial number of model CTCs added, and N2 is the number of free model CTCs in the supernatant after capture, which are calculated based on the fluorescence intensity of the sample, volume, and standard curve.
[0069] M1 is the initial amount of model TDEs added (μg), and M2 is the amount of free TDEs in the supernatant after capture, which was calculated based on the fluorescence intensity of the sample, volume, and standard curve.
[0070] (2) Effect of the amount of filler in the capture column on the capture efficiency
[0071] In order to investigate the effect of the filler volume in the capture column on the capture efficiency of circulating tumor cells and tumor exosomes, the amount of capture column immunosorbent filler was set to 100, 200, 300, 400, and 500 mg, respectively.
[0072] First, a metastasis-promoting derivative removal system was installed (including multiple capture columns, intravenous catheters, indwelling needles and peristaltic pumps; the indwelling needles, intravenous catheters, capture columns, peristaltic pumps, intravenous catheters, and indwelling needles were connected in sequence; the capture columns were filled with the immunosorbent prepared in Example 1); then, 2×10 5 MDA-MB-468 cells (200 μL, resuspended in PBS) and 50 μg of exosomes from MDA-MB-468 cells labeled with DiR in advance (resuspended in 200 μL PBS), supplemented with PBS to 10 mL. Turn on the peristaltic pump, adjust to a flow rate of 10 mL / min, circulate for 30 minutes, and then collect the circulating medium to separate the uncaptured MDA-MB-468 cells and tumor exosomes.
[0073] Specifically, the circulating medium was centrifuged at 1000 rpm for 3 min; the supernatant was concentrated to 200 μL using an Amicon Ultra 10-kDa filter (Millipore Sigma) to obtain free exosomes, and the cell pellet was resuspended with 200 μL PBS to obtain free tumor cells. The fluorescence intensity of the samples was measured using a multifunctional microplate reader, and the respective clearance efficiencies were calculated according to the formula.
[0074] The capture efficiency of cancer cells and their exosomes increased with the increase of the amount of immunosorbent filled in the capture column, and the clearance efficiency almost reached the peak at 300 mg. For model CTCs and TDEs, the capture efficiency reached 53.5 ± 5.9% and 42.02 ± 3.0%, respectively. Figure 5 As shown in C.
[0075] (3) Effect of cycle time on capture efficiency
[0076] Groups of 10, 20, 30, 40, 50, and 60 min were set up, and extracorporeal circulation simulation experiments were carried out according to the above method, and their respective clearance efficiencies were calculated.
[0077] By investigating the effect of cycle time on the removal efficiency, we found that the capture efficiency increases with the increase of cycle time, e.g. Figure 5 As shown in Figure 2D, the capture efficiency of model CTCs reached a peak at 30 min, while that of model TDEs reached a peak in a shorter time, which may be related to the higher frequency of collision between exosomes and immunoadsorbents.
[0078] Example 4 Release and collection of circulating tumor cells and tumor exosomes in immunoadsorbents
[0079] (1) Elution of circulating tumor cells and tumor exosomes from immunoadsorbents
[0080] The immunosorbent was removed from the capture column, incubated with 0.25% trypsin-EDTA at room temperature for 3 min, then diluted with PBS at a ratio of 1:10, filtered through a 300-mesh sieve, and then centrifuged at 2000 rpm for 3 min. The cell pellet was collected from the filtrate and then used for re-cultivation.
[0081] The supernatant was retained and designated as supernatant 1. The immunosorbent was then incubated with glycine-HCl buffer at pH 2.2 at room temperature for 5 minutes, centrifuged at 1000 rpm for 3 minutes, and the supernatant was collected and designated as supernatant 2.
[0082] Finally, supernatant 1 and supernatant 2 were combined and concentrated using Amicon Ultra 10-kDa ultrafiltration tubes (MilliporeSigma).
[0083] (2) Characterization of eluted tumor exosomes
[0084] TEM images of exosomes released from the immunosorbent were obtained using the H-7650TEM system. PBS-diluted samples were dried on Formvar-coated copper grids and stained with 2% phosphotungstic acid.
[0085] The size and concentration of exosomes released from the immunosorbents were determined by nanoparticle tracking analysis (NTA) using ZetaView (Particle Metrix, Meerbusch, Germany).
[0086] (3) Activity analysis of released tumor cells
[0087] The released tumor cells were co-stained with Calcein-AM and PI for 15 minutes, washed three times with PBS, added to a slide, covered with a cover slip, and observed and photographed under an inverted fluorescence microscope.
[0088] (4) Analysis of the proliferation ability of released tumor cells
[0089] The released tumor cells were inoculated into 96-well plates, with 100 μL DMEM (purchased from Jiangsu Keygen Biotechnology, supplemented with 10% FBS) per well, and cultured in a 37°C, 5% CO2 incubator for 5 days. On the 1st, 3rd and 5th day, the cell viability was measured using a CCK-8 kit (purchased from Jiangsu Keygen Biotechnology), and the OD value at 450 nm was recorded using a microplate reader.
[0090] like Figure 6 As shown in A, the release efficiencies of CTCs and TDEs were as high as 92.7±1.2% and 85.6±1.3%, respectively.
[0091] like Figure 6As shown in B, the released TDEs exhibit a typical saucer-like structure.
[0092] like Figure 6 As shown in C, the size of the released TDEs is 139.5 nm.
[0093] like Figure 6 As shown in D, due to the staining of live cells by Calcein-AM and dead cells by PI, it can be found that almost no cell death occurs and the released tumor cells have good cell viability, indicating that tumor cells are almost unaffected by the capture and release process. Due to the rarity of CTCs, cell re-culture can be performed to meet the needs of tumor diagnosis and detection.
[0094] like Figure 6 As shown in E, as the culture time increases, the OD value continues to increase, indicating that the number of cells is increasing. Therefore, through cell re-culture, it is found that the released cells have good proliferation ability.
[0095] Through the above studies, it is proved that the removal system of the present invention can achieve efficient removal of circulating tumor cells and tumor exosomes, and is expected to reduce the chance of tumor metastasis. The activity rate of the captured cells remains above 90%, and can be directly used for culture; the released tumor exosomes maintain a complete vesicle structure, which will provide valuable tumor samples for tumor diagnosis and detection, and has important medical significance.
[0096] Example 5 A metastasis-promoting derivative perfusion system
[0097] like Figure 1 As shown, a metastasis-promoting derivative perfusion system includes an arterial pressure gauge 1, a blood pump 2, a heparin pump 3, an inflow pressure gauge 4, a metastasis-promoting derivative removal system 5, a degassing system 6, and a venous pressure gauge 7.
[0098] The arterial pressure gauge 1, the blood pump 2, the heparin pump 3, the inflow pressure gauge 4, the metastasis-promoting derivative removal system 5, the degassing system 6, and the venous pressure gauge 7 are connected in sequence through an extracorporeal blood pipeline.
[0099] The blood pump 2 provides power for extracorporeal blood circulation; the heparin pump 3 provides heparin to the blood to prevent coagulation; the metastatic derivative removal system 5 is used to remove metastatic derivatives, such as circulating tumor cells, tumor exosomes, etc.; the purified blood is removed from the air bubbles by the degassing system 6, and after the venous pressure gauge 7 detects that the blood is qualified, it is delivered to the patient's body.
[0100] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.
Claims
1. A metastasis-promoting derivative clearance system, It is characterized in that It includes one or more capture columns, intravenous catheters, indwelling needles and peristaltic pumps; the removal system is connected in the order of indwelling needles, intravenous catheters, capture columns, peristaltic pumps, intravenous catheters and indwelling needles; The capture column is filled with an immunosorbent.
2. The metastasis-promoting derivative clearance system according to claim 1, It is characterized in that The surface or interior of the immunoadsorbent is embedded with a ligand that specifically binds to the metastasis-promoting derivative.
3. The metastasis-promoting derivative clearance system according to claim 2, It is characterized in that The ligand is one or more of tumor-specific antibodies, polypeptides, nucleic acid aptamers or small molecules; the small molecule is hyaluronic acid or lectin.
4. The metastasis-promoting derivative clearance system according to claim 2, It is characterized in that The carrier material of the immunosorbent is one or more of agarose, polystyrene-divinylbenzene resin, polyethylene, polyvinyl alcohol, polypropylene, polyacrylamide, polyacrylic acid, polyacrylate, cellulose, chitin or carbon nanotubes, preferably agarose.
5. The metastasis-promoting derivative clearance system according to claim 4, It is characterized in that The immunosorbent is prepared according to the following method: using agarose gel microspheres as carriers, using epichlorohydrin to epoxidize the agarose gel microspheres, and in a carbonate buffer, using the amino group or thiol group of the ligand molecule to undergo a ring-opening reaction with the epoxy group to achieve coupling, thereby preparing the immunosorbent.
6. The metastasis-promoting derivative clearance system according to claim 1, It is characterized in that The immunosorbent is a spherical structure with an average particle size of 10-1000 μm and a porous structure with a pore size distribution range of 10 nm-200 nm.
7. The metastasis-promoting derivative clearance system according to claim 1, It is characterized in that The immunosorbent allows large-sized metastasis-promoting derivatives to be specifically adsorbed on the surface; small-sized metastasis-promoting derivatives can be specifically adsorbed on the surface or adsorbed inside through the dual effects of molecular sieving and specific adsorption.
8. The metastasis-promoting derivative clearance system according to claim 1, It is characterized in that The metastasis-promoting derivatives include circulating tumor cells, tumor exosomes, cytokines that promote metastasis, circulating tumor DNA, and tumor-associated cells that promote metastasis.
9. The metastasis-promoting derivative clearance system according to claim 8, It is characterized in that 0.25% trypsin-EDTA was used to elute the specifically bound circulating tumor cells; pH 2.2 glycine-HCl buffer was used to elute the specifically bound tumor exosomes and collect them for downstream analysis.
10. A metastasis-promoting derivative perfusion system, comprising an arterial pressure gauge, a blood pump, a heparin pump, an inflow pressure gauge, a degassing system, and a venous pressure gauge, It is characterized in that It also includes the metastasis-promoting derivative removal system according to any one of claims 1 to 9; the arterial pressure gauge, blood pump, heparin pump, inflow pressure gauge, metastasis-promoting derivative removal system, degassing system, and venous pressure gauge are sequentially connected through an extracorporeal blood pipeline; The blood pump provides power for extracorporeal blood circulation; the heparin pump provides heparin to the blood to prevent blood coagulation; The metastasis-promoting derivative removal system is used to remove metastasis-promoting derivatives; the purified blood is delivered to the patient after the bubbles are removed by the degassing system and the blood is tested as qualified by the venous pressure gauge.
Citation Information
Patent Citations
Method and device to detect and treat diseases such as tumor or virus infection
CN103732271A
Blood perfusion adsorbent for removing circulating tumor cells and preparation method thereof
CN113101900A
Extracorporeal Removal of Microvesicular Particles
US20090304677A1
